ShapeTX Stock

shapetx.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $138.25MM

Shape Therapeutics is a biotechnology company focused on developing breakthrough RNA technologies to shape the future of gene therapy.

Register To Buy and Sell Shares

For more details on financing and valuation for ShapeTX, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access ShapeTX’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ShapeTX.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About ShapeTX’s Stock

Can you buy ShapeTX’s stock?
ShapeTX is not publicly traded on NYSE or NASDAQ in the U.S. To buy ShapeTX’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell ShapeTX’s stock?
Yes, you can sell stock of a private company like ShapeTX. Forge can help you sell your ShapeTX stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is ShapeTX’s stock price?
ShapeTX is a privately held company and therefore does not have a public stock price. However, you may access ShapeTX’s private market stock price with Forge Data.
What is ShapeTX’s stock ticker symbol?
ShapeTX does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
Otsuka Pharmaceutical and Shape TX have announced a partnership to develop adeno-associated virus (AAV) gene therapies for eye diseases. The collaboration will leverage Shape TX's AI-driven AAVid platform and Otsuka's expertise in genetic payload design and ophthalmology. The deal includes an initial payment to Shape TX, along with potential development, regulatory, and sales milestone payments exceeding $1.5 billion.
ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond
Shape Therapeutics (Shape TX) plans to present seven presentations featuring its technology platforms at the 26th American Society for Gene and Cell Therapy Annual Meeting. The presentations will include new data from the company's RNAfix, RNAswap, AAVid, and TruStable platforms. Shape TX aims to use AI and RNA to end genetic diseases.
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.